Background
• The short-term and long-term clinical outcome of patients receiving radioactive iodine (RAI) treatment for thyrotoxicosis differs in various studies.
• There is little consensus regarding the most appropriate dose of RAI to be administered.
• The range of activities currently prescribed varies between 200-800 MBq, with majority of patients receiving 400-600 MBq.
• In our centre, all patients receive a standard fixed dose of 400 MBq. Treatment is considered to have failed, if patients remain hyperthyroid at 12 months and a repeat 400 MBq is considered.
Aim
To determine:
• The number of patients who remained hyperthyroid one year post RAI treatment • The number of patients who required a second dose of RAI • The cure rate with a dose of 400MBq at the end of one year
Results
• 59 patients were included in the audit.
• 16 patients were male • 43 patients were female • Average age: 59.14 yrs (ranging from 25-88 years)
Conclusion
In our centre, a standard 400MBq dose of RAI has a cure rate of 81.36% at 6 months and 76.27% at 12 months, which is in line with the figures quoted in the literature.
Method
• We did a retrospective study of all patients treated with RAI at our hospital over a 3 year period.
• All patients received a fixed 400 MBq dose.
• TSH and FT4 levels were recorded at diagnosis, the time of RAI, 6 months and one year post-RAI.
• Anti-thyroid medication was discontinued for 10 days prior to RAI therapy.
• Failure rate in terms of persistence of hyperthyroidism at the end of one year was calculated.
At the time of diagnosis:
• 37% (22 patients 
Multiple Doses of RAI:
Of 59 patients investigated 6 patients required multiple doses of RAI: 2 had previous doses of RAI 4 received future doses of RAI
